Description
BSE announces listing of 91,86,490 new equity shares of Suven Life Sciences Ltd issued through warrant conversion, effective August 28, 2025.
Summary
BSE has announced the listing of 91,86,490 new equity shares of Suven Life Sciences Ltd (Scrip Code: 530239) effective from Thursday, August 28, 2025. These shares were issued at a premium of Rs.133/- to non-promoters on a preferential basis pursuant to conversion of warrants.
Key Points
- 91,86,490 new equity shares of Rs. 1/- each listed
- Issue price: Rs. 134/- (Rs. 1 face value + Rs. 133 premium)
- Securities rank pari-passu with existing equity shares
- Distribution numbers: 218073718 to 227260207
- Date of allotment: July 16, 2025
- ISIN: INE495B01038
Regulatory Changes
No regulatory changes announced. Standard listing procedure for warrant conversion.
Compliance Requirements
- Trading members informed of new securities availability for trading
- Lock-in restrictions apply to all newly issued shares
- Shares subject to standard listing compliance requirements
Important Dates
- Allotment Date: July 16, 2025
- Trading Commencement: August 28, 2025
- Lock-in Period End: March 9, 2026
Impact Assessment
The listing increases Suven Life Sciences’ equity base significantly with nearly 92 lakh new shares. The 18-month lock-in period until March 2026 means these shares cannot be freely traded immediately, limiting short-term supply impact. The preferential allotment to non-promoters may dilute existing shareholding patterns.
Impact Justification
Standard equity listing with lock-in period, moderate impact on share capital and trading